308 related articles for article (PubMed ID: 28712052)
1. Pharmacotherapy for Pediatric Neurogenic Bladder.
Kroll P
Paediatr Drugs; 2017 Oct; 19(5):463-478. PubMed ID: 28712052
[TBL] [Abstract][Full Text] [Related]
2. [Neurogenic disorders of bladder emptying in childhood].
Rösch W
Wien Med Wochenschr; 1998; 148(22):511-4. PubMed ID: 10096139
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for neurogenic detrusor overactivity.
Chancellor MB; Anderson RU; Boone TB
Am J Phys Med Rehabil; 2006 Jun; 85(6):536-45. PubMed ID: 16715024
[TBL] [Abstract][Full Text] [Related]
4. Home Urodynamic Pressures and Volume Measurement for the Neurogenic Bladder: Initial Validation Study.
Hidas G; Soltani T; Billimek J; Selby B; Kelly MS; McLorie G; Wehbi E; Khoury AE
J Urol; 2017 Dec; 198(6):1424-1429. PubMed ID: 28587917
[TBL] [Abstract][Full Text] [Related]
5. Urodynamic findings during the filling phase in neurogenic bladder patients with or without vesicoureteral reflux who have undergone sacral neuromodulation.
Chen G; Liao L; Wang Y; Ying X
Neurourol Urodyn; 2020 Jun; 39(5):1410-1416. PubMed ID: 32282088
[TBL] [Abstract][Full Text] [Related]
6. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
Naqvi S; Clothier J; Wright A; Garriboli M
J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
[TBL] [Abstract][Full Text] [Related]
7. Urodynamic parameters development and complications of clean intermittent self-catheterization in Chinese schoolchildren with neurogenic underactive bladder.
Wang QW; Song DK; Zhang XP; Wu YD; Zhang RL; Wei JX; Wen JG
Urol Int; 2011; 86(4):461-5. PubMed ID: 21555862
[TBL] [Abstract][Full Text] [Related]
8. The effects of long-term medical treatment combined with clean intermittent catheterization in children with neurogenic detrusor overactivity.
Lehnert T; Weisser M; Till H; Rolle U
Int Urol Nephrol; 2012 Apr; 44(2):335-41. PubMed ID: 21779920
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction.
Sager C; Sanmartino M; Burek C; Gomez YR; Vazquez Patiño M; Weller S; Ruiz J; Lopez Imizcoz F; Tessi C; Szklarz T; Corbetta JP
J Pediatr Urol; 2020 Oct; 16(5):655.e1-655.e6. PubMed ID: 32800710
[TBL] [Abstract][Full Text] [Related]
11. The management of paediatric neurogenic bladder: an approach in a resource-poor setting.
Maison POM; Lazarus J
Paediatr Int Child Health; 2017 Nov; 37(4):280-285. PubMed ID: 28714784
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Urodynamic Results of Repeated Intradetrusor Onabotulinum Toxin A Injections in Refractory Neurogenic Detrusor Overactivity: Up to 5 Injections in a Cohort of Children With Myelodysplasia.
Sekerci CA; Tanidir Y; Garayev A; Akbal C; Tarcan T; Simsek F
Urology; 2018 Jan; 111():168-175. PubMed ID: 28943369
[TBL] [Abstract][Full Text] [Related]
13. Detrusor overactivity in spina bifida: how long does it need to be treated?
Ab E; Dik P; Klijn AJ; van Gool JD; de Jong TP
Neurourol Urodyn; 2004; 23(7):685-8. PubMed ID: 15382196
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting the success of intradetrusor onabotulinum toxin-A treatment in children with neurogenic bladders due to myelomeningocele: The outcomes of a large cohort.
Danacioglu YO; Keser F; Ersoz C; Polat S; Avci AE; Kalkan S; Silay MS
J Pediatr Urol; 2021 Aug; 17(4):520.e1-520.e7. PubMed ID: 33712371
[TBL] [Abstract][Full Text] [Related]
15. Early treatment improves urodynamic prognosis in neurogenic voiding dysfunction: 20 years of experience.
Costa Monteiro LM; Cruz GO; Fontes JM; Vieira ETRC; Santos EN; Araújo GF; Ramos EG
J Pediatr (Rio J); 2017; 93(4):420-427. PubMed ID: 28431215
[TBL] [Abstract][Full Text] [Related]
16. Video-urodynamics efficacy of sacral neuromodulation for neurogenic bladder guided by three-dimensional imaging CT and C-arm fluoroscopy: a single-center prospective study.
Shan S; Zhu W; Zhang G; Zhang Q; Che Y; Wen J; Wang Q
Sci Rep; 2022 Sep; 12(1):16306. PubMed ID: 36175471
[TBL] [Abstract][Full Text] [Related]
17. Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study.
Lazzeri M; Calò G; Spinelli M; Malaguti S; Guerrini R; Salvadori S; Beneforti P; Regoli D; Turini D
J Urol; 2006 Nov; 176(5):2098-102. PubMed ID: 17070267
[TBL] [Abstract][Full Text] [Related]
18. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
[TBL] [Abstract][Full Text] [Related]
19. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Álvares RA; Araújo ID; Sanches MD
BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of onobotulinumtoxinA as a therapeutic option for pediatric neurogenic detrusor overactivity.
Peard LM; Pope JC; Dmochowski R
Expert Rev Neurother; 2023; 23(9):763-774. PubMed ID: 37556757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
